2025 fourth_quarter Filing

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INCforUnknown

Expenses

$610K

Method: A

Filed

February 4, 2026

View Original Document

Lobbying Activities

Health IssuesView all

Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act

Contacted:HOUSE OF REPRESENTATIVES, SENATE

Medicare/MedicaidView all

Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025; H.R. 946/S. 1862, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals Education about cancer and Medicare screening coverage, including H.R. 842/S. 339, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Lobbyists (5)

SARAH ELIZABETH NORDSTROM

ms KATHARINE TROLLER BOND

CHRISTOPHER CUNNINGHAM

BILL DAVIS